Table 1. Main characteristics of included studies in the systematic review and meta-analysis.
| First author,year | Age | Main Ethnicity | Sample size | Gender | Gene SNPs | Genotyping method | Site of metastasis | Survival analysis | Source of HR | Follow-up time (month) | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Male | Female | ||||||||||
| Liu, 2017 | 62.3 (46–72) | Asian | 68 | 40 | 28 | VEGFR2/VEGFR3 | PCR-RFLPs | Lung/Lymphatic/Osseous/Hepatic/Adrenal/Other | OS | Reported | median 15 (6–23) |
| Dornbusch, 2016 | 59 (53.5–67.0) | Caucasian | 121 | 95 | 26 | VEGFA/VEGFR1/VEGFR2/VEGFR3 | TaqMan | NA | PFS/OS | Reported | median 24.6 (10.5–41.6) |
| Beuselinck, 2016 | 59 | Caucasian | 157 | 113 | 44 | VEGFR1 | Sequenom MassArray platform | Lung/Liver/Bone/Brain | PFS/OS | Reported | median 77 (1–116) |
| Motzer, 2014 | NA | Caucasian | 202 | 135 | 67 | VEGFR3 | TaqMan | NA | PFS | Reported | NA |
| Beuselinck, 2014 | 59 | Caucasian | 91 | 62 | 29 | VEGFR1 | Sequenom MassArray platform | Lung/Liver/Bone/Brain | OS | Reported | median 50 (1–75) |
| Beuselinck, 2013 | 59 (38–84) | Caucasian | 88 | 60 | 28 | VEGFR3 | Sequenom MassArray platform | Lung/Liver/Bone/Brain | PFS/OS | Reported | median 46 (1–73) |
| Scartozzi, 2013 | 64 (47–85) | Caucasian | 84 | 65 | 19 | VEGFA/VEGFR3 | TaqMan | NA | PFS | SC | maximum 42/SC |
| Garcia-Donas, 2011 | 65 (42–87) | Caucasian | 89 | 65 | 24 | VEGFA/VEGFR2/VEGFR3 | KASPar SNP genotyping system | Lung/Lymph nodes/Bone/Kidney/Liver | PFS/OS | Reported | median 21.2 (8.4–25.6) |
SNPs, single-nucleotide polymorphisms; VEGFA, vascular endothelial growth factor A; VEGFR, vascular endothelial growth factor receptor; OS, overall survival; PFS, progression-free survival.
NA, not available; SC, survival curve.